RTTR Research and Charts

RTTR - Ritter Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2020-07-31 (Delayed quote data 2025-01-03)

Last 4.54	Change ⇑ +0.34 (+8.10%)	Volume 37,574
	Open 4.22	High 4.59	Low 4.22

8EMA (Daily) 4.25	40EMA (Daily) 3.72	50EMA (Daily) 3.46	STO (Daily) 71.100	MACD Hist (Daily) -0.053
8EMA (Weekly) 3.858	40EMA (Weekly) 1.75	50EMA (Weekly) 1.55	STO (Weekly) 81.660	MACD Hist (Weekly) 0.486


Company Profile
Ritter Pharmaceuticals Inc develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing a variety of conditions including: gastrointestinal diseases, immuno-oncology, metabolic, and liver disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.